Jazz Pharmaceuticals has entered a definitive agreement to sell its rights to Prialt (ziconotide) intrathecal infusion to TerSera Therapeutics LLC for $80 million in cash. The transaction, subject to customary closing conditions, is expected to close 3Q18. As part of the transaction, TerSera will offer employment to a majority of the Jazz employees dedicated to Prialt. Prialt is the only FDA approved, non-opioid agent indicated for the management of severe chronic pain in adult patients for w...